ESTRO37_ProgrammeBook

10:40 > A randomized phase II study testing for optimal strategy for patients with high risks rectal cancer

T. Vuong (Canada), P. Kavan, A.G. Martin, L. Azoulay, D. Donath, C. Lavoie, E. Ferland, N. Nguyen, C.A. Vasilevsky, S. Desgroseilliers, S. Drolet, C. Richard, M. Boutros, G. Batist

SUNDAY 22 APRIL 2018

OC-0279

10:50 > Proctitis after brachytherapy for rectal cancer: clinical and dosimetric factors - The HERBERT study E.C. Rijkmans (The Netherlands), R.A. Nout, E.M. Kerkhof, A. Cats, B. Van Triest, A. Inderson, R.P.J. Van den Ende, M.S. Laman, M. Ketelaars, C.A.M. Marijnen 11:00 > Time interval between chemoradiation and surgery and postoperative complications in rectal cancer A.M. Couwenberg (The Netherlands), H.M. Verkooijen, S. Hoendervangers, W.M.U. Van Grevenstein, M.P.W. Intven

OC-0280

OC-0281

11:10 > Complete response after short-course radiotherapy versus chemoradiation in advanced rectal cancer

S. Hoendervangers (The Netherlands), A.M. Couwenberg, M.P.W. Intven, W.M.U. Van Grevenstein, H.M. Verkooijen

OC-0282

11:20 > Prognostic value of serum NPY hypermethylation in neoadjuvant chemoradiotherapy for rectal cancer A.L. Appelt (United Kingdom), R.F. Andersen, J. Lindebjerg, A. Jakobsen 11:30 > First results of the French cohort ANABASE: treatment and outcome in non-metastatic anal cancer

OC-0283

V. Vendrely (France), C. Lemanski, E. François, E. Barbier, N. Baba Hamed, N. Bonichon-Lamichhane, A. De La Rochefordière, O. Bouché, D. Tougeron, O. Diaz, P. Pommier, P. Ronchin, M. Saliou, J. Cretin, C. Lepage, L. Quéro

OC-0284

PROFFERED PAPERS BT 3: Brachytherapy prostate, head and neck

10:30 - 11:45  | ROOM 129-130 Chair: C. Salembier (Belgium) Chair: P. Niehoff (Germany)

10:30 > External beam (EBRT) and HDR brachytherapy (BT) in prostate cancer: impact of EBRT volume H. Tharmalingam (United Kingdom), Y. Tsang, A. Choudhury, P. Hoskin

OC-0285

SCIENTIFIC PROGRAMME | Programme and Exhibition Guide

114